<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MDM</journal-id>
<journal-id journal-id-type="hwp">spmdm</journal-id>
<journal-id journal-id-type="nlm-ta">Med Decis Making</journal-id>
<journal-title>Medical Decision Making</journal-title>
<issn pub-type="ppub">0272-989X</issn>
<issn pub-type="epub">1552-681X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0272989X13480130</article-id>
<article-id pub-id-type="publisher-id">10.1177_0272989X13480130</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Use of Multiparameter Evidence Synthesis to Assess the Appropriateness of Data and Structure in Decision Models</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Epstein</surname><given-names>David</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Mochón</surname><given-names>Leticia García</given-names></name>
<degrees>MSc</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Espín</surname><given-names>Jaime</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Soares</surname><given-names>Marta O.</given-names></name>
<degrees>MSc</degrees>
</contrib>
</contrib-group>
<aff id="aff1-0272989X13480130">University of York, York, UK (DE, MOS)</aff>
<aff id="aff2-0272989X13480130">Escuela Andaluza de Salud Pública, Granada, Spain (LGM, JE)</aff>
<author-notes>
<corresp id="corresp1-0272989X13480130">David Epstein, Faculty of Economics, University of Granada, Granada, 18071, Spain; e-mail: <email>david.epstein@york.ac.uk</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2013</year>
</pub-date>
<volume>33</volume>
<issue>5</issue>
<fpage>715</fpage>
<lpage>730</lpage>
<history>
<date date-type="received">
<day>10</day>
<month>12</month>
<year>2009</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>1</month>
<year>2013</year>
</date>
</history>
<abstract>
<p><bold>Objectives.</bold> Decision models for health technology appraisal are defined by their structure and data. Often there are alternatives for how the model might be specified and what data to include, and criteria are required to guide these choices. This study uses multiparameter evidence synthesis (MPES) to synthesize data from diverse sources and test alternative model structures. The methods are illustrated by a comparison of blood ketone testing versus urine ketone testing for young people with Type 1 diabetes. <bold>Methods.</bold> Two approaches were compared. A simple statistical model (Model 1) was used to estimate the difference in the rates of adverse events from the outcome data of a randomized controlled trial (RCT). MPES (Model 2) was constructed to synthesize data on outcome and process variables from the RCT with data from nonrandomized studies on specificity and sensitivity. Sensitivity analyses were carried out using alternative model specifications for the MPES, and the consistency of the data was evaluated. <bold>Results</bold>. Model 1 estimated that the mean difference in the rate of adverse events per day was 0.0011 (95% confidence interval 0.0005–0.00229) lower with blood ketone testing. Model 2 estimated a similar outcome but also estimated parameters for which there were no direct data, including the prevalence of high ketone levels and the sensitivity and specificity of the tests as used in the home. <bold>Conclusions</bold>. Model 1, which used only outcome data from an RCT, showed that blood ketone testing is more effective but did not explain why this is so. Model 2, estimated by MPES, suggested that the blood test is more accurate and that patients are more likely to comply with the protocol.</p>
</abstract>
<kwd-group>
<kwd>ketoacidosis</kwd>
<kwd>Type 1 diabetes</kwd>
<kwd>diagnostic testing</kwd>
<kwd>multiparameter evidence synthesis</kwd>
<kwd>cost-effectiveness analysis.</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Decision models have become an established technique to assess the effectiveness and cost-effectiveness of health care technologies. A multistate model offers a framework to structure a decision problem by relating key events mathematically; an example is state transition modeling, where important states are defined and possible transitions between these are tracked over time to reproduce disease progression or a sequence of treatments. The time patients spend in states is associated with a utility score and costs, which accumulate over time to define total costs and quality-adjusted life years, key elements in the evaluation of cost effectiveness. The use of decision models ultimately allows predictions to be made, possibility extrapolating beyond the time frame of the available evidence, and quantify uncertainty in the decision.</p>
<p>There are 2 important steps in specifying a decision model.<sup><xref ref-type="bibr" rid="bibr1-0272989X13480130">1</xref></sup> The first is to define its structure (the states and permitted transitions), a representation of the natural history of the disease, which might be altered or palliated by intervention. The parameters of the model are numbers that quantify this process (e.g., the speed at which transitions between states occur, and the costs or health-related quality of life for each unit of time spent in each health state). The second step is to find and summarize the data to inform the values of these parameters. Conventional multistate decision models use separate platforms to estimate parameters (e.g., statistical software) and make predictions (e.g., a spreadsheet or TreeAge). This approach is pragmatic and flexible but has potential drawbacks. There is often a choice of structures, leading to model uncertainty.<sup><xref ref-type="bibr" rid="bibr2-0272989X13480130">2</xref></sup> Introducing additional model states, for example, may improve model predictions (internal validity) or increase generalizability (external validity). However, there is a cost to greater complexity, known as overfitting. A model with more parameters requires more data to estimate those parameters. Where data are insufficient, predictions may be unreliable. In this case the model can be driven by idiosyncrasies in the data or pet theories of the analyst or advisors and can miss more general patterns.<sup><xref ref-type="bibr" rid="bibr3-0272989X13480130">3</xref></sup> There is also often a choice of data that could be used to populate the model. A single data source may not have measured all the outcomes required by a multistate model, and hence analysts sometimes use different data sources to estimate different parameters. However, using multiple data sources raises the possibility that at least one of these will be biased (e.g., the study was flawed) or inconsistent (the samples were not drawn from the same population<sup><xref ref-type="bibr" rid="bibr4-0272989X13480130">4</xref></sup>). There is also a risk of consciously or unconsciously being selective in the data chosen. It has been noted that in most decision models, each parameter in the model is, by “marvelous coincidence,” populated by a single independent piece of data.<sup><xref ref-type="bibr" rid="bibr5-0272989X13480130">5</xref></sup> In reality, there may be data on functions of parameters that cannot be incorporated easily into a given model structure. Such information might end up being excluded or not searched for. Conventional decision models do not offer objective criteria for choosing between alternative structures, cannot easily use data that do not correspond directly with a model parameter, and do not offer methods for checking the consistency of data.</p>
<p>Multiparameter evidence synthesis (MPES) provides an alternative method of implementing decision models that is well recognized in the literature.<sup><xref ref-type="bibr" rid="bibr6-0272989X13480130">6</xref></sup> MPES allows a comprehensive framework for specification of the model structure, parameter estimation from data from diverse sources, and validation (comparing the goodness of fit of model predictions against the data and checking the consistency of these data).<sup><xref ref-type="bibr" rid="bibr5-0272989X13480130">5</xref></sup> MPES promotes a consistent model structure and ensures proper propagation of parameter estimates, uncertainty, and correlations between parameters through the model. Incorporating correlations between parameters (“borrowing strength”) can improve precision of predictions and, in cases where some data are missing, reduce bias.<sup><xref ref-type="bibr" rid="bibr7-0272989X13480130">7</xref><xref ref-type="bibr" rid="bibr8-0272989X13480130"/>–<xref ref-type="bibr" rid="bibr9-0272989X13480130">9</xref></sup> MPES can use data on functions of parameters, which are difficult to incorporate in conventional decision models. This allows the model to make use of a broader range of sources of evidence, avoiding the need to leave out data items that do not “fit” into the model structure. Provided data are available on more functions of parameters than the number of parameters, the model can estimate parameters where there are no directly observed data. These may reveal causal mechanisms that help explain how the intervention works.<sup><xref ref-type="bibr" rid="bibr10-0272989X13480130">10</xref></sup> MPES can compare the goodness of fit of alternative model structures (if fitted to the same data set) and check the consistency of data points from diverse sources.<sup><xref ref-type="bibr" rid="bibr5-0272989X13480130">5</xref></sup></p>
<p>The aim of this article is to use MPES to combine evidence from diverse sources and test alternative model structures. The method is illustrated by a comparison of blood ketone testing versus urine ketone testing for young people with Type 1 diabetes as part of an appraisal undertaken on behalf of the Health Technology Assessment Agency of Andalucía (AETSA), Spain. In this example, data are available from a randomized controlled trial (RCT) on health outcomes (adverse events), the rates of positive and negative test results, and adherence with the test protocol for both technologies. Furthermore, there are independent data from 2 other studies that estimated the performance (sensitivity and specificity) of the tests. The MPES is used to estimate variables for which there are no directly observed data (e.g., the sensitivity and specificity of the tests as used in the RCT). Alternative model specifications are compared for goodness of fit, and the consistency of data is assessed. The analysis is conducted using Monte-Carlo Markov chain (MCMC) simulation implemented in WinBUGS.<sup><xref ref-type="bibr" rid="bibr11-0272989X13480130">11</xref></sup></p>
<sec id="section1-0272989X13480130" sec-type="methods">
<title>Methods</title>
<sec id="section2-0272989X13480130">
<title>The Illustrative Decision Problem and Description of the Technology</title>
<p>The decision problem is to compare the effectiveness of blood monitoring for detecting high ketone levels versus the urine ketone test. The health outcome is measured as acute adverse events. There are (potentially) 2 types of relevant acute adverse events in this population: diabetic ketoacidosis (DKA) and hypoglycemia. A cost-effectiveness analysis of these technologies is published elsewhere.<sup><xref ref-type="bibr" rid="bibr12-0272989X13480130">12</xref></sup></p>
<p>Diabetic ketoacidosis is an acute, potentially life-threatening complication of Type 1 diabetes in young people, usually requiring emergency medical care. In principle, DKA may be preventable with improved outpatient treatment and self-management with glucose and ketone monitoring.<sup><xref ref-type="bibr" rid="bibr13-0272989X13480130">13</xref></sup> Guidelines recommend regular blood glucose monitoring, which patients are expected to undertake 3 or 4 times a day<sup><xref ref-type="bibr" rid="bibr14-0272989X13480130">14</xref></sup> (the model assumes that all patients comply with glucose monitoring). In addition, patients are recommended to test ketone levels at home if they experience symptoms of ketosis, such as nausea or abdominal pain (known as a sick day), or have 2 high successive glucose readings. The conventional ketone test uses urine strips. A newer technology, blood ketone testing, tests blood ketone levels directly. Blood ketone testing is claimed to offer greater accuracy and ease of use, although at a higher acquisition cost.<sup><xref ref-type="bibr" rid="bibr13-0272989X13480130">13</xref></sup> About 1 in 1000 young people in Spain have Type 1 diabetes.<sup><xref ref-type="bibr" rid="bibr15-0272989X13480130">15</xref></sup></p>
<p>The following data were identified by a systematic review.<sup><xref ref-type="bibr" rid="bibr12-0272989X13480130">12</xref></sup> An RCT estimated the number of adverse events (ketoacidosis and hypoglycemia) requiring medical assistance during 6 months of follow-up.<sup><xref ref-type="bibr" rid="bibr14-0272989X13480130">14</xref></sup> The RCT also estimated the frequency of sick days and high glucose days, the frequency with which the tests are used on these days, and the frequency of positive test results on these days, comparing blood testing and urine testing. There are also 2 nonrandomized studies that estimated sensitivity and specificity of both tests.<sup><xref ref-type="bibr" rid="bibr16-0272989X13480130">16</xref>,<xref ref-type="bibr" rid="bibr17-0272989X13480130">17</xref></sup></p>
</sec>
<sec id="section3-0272989X13480130">
<title>Model Structures and Data</title>
<sec id="section4-0272989X13480130">
<title>Overview</title>
<p>Two alternative model structures are presented. Both models estimate the expected rate per person-day of acute adverse events for young people using the tests. Model 1 is based exclusively and directly on the number of adverse events found by the RCT. This model represents a fairly typical statistical analysis that would be applied to make inferences about the difference in the rates of adverse events between the 2 technologies. Model 2 incorporates a much broader data set and has a more complex decision tree structure with parameters estimated by an MPES.</p>
</sec>
<sec id="section5-0272989X13480130">
<title>Model 1</title>
<p>The structure of Model 1 is very simple and is shown in <xref ref-type="fig" rid="fig1-0272989X13480130">Figure 1</xref>. The RCT reported the total number of acute adverse events requiring medical attention: 11 events in 29.1 patient-years in the blood ketone group and 22 events in 29.9 patient-years in the urine ketone group.<sup><xref ref-type="bibr" rid="bibr14-0272989X13480130">14</xref></sup> However, the RCT did not distinguish between the number of hypoglycemic events and DKA (hyperglycemic events). The analysis of these data in Model 1 is as follows. The total numbers of DKA and hypoglycemic events <italic>R<sub>j</sub></italic> per day in <italic>N<sub>j</sub></italic> patient-days of follow-up in the blood ketone group <italic>j</italic> = 1 and the urine ketone group <italic>j</italic> = 2 follow a Poisson distribution with mean rate of events per day λ<sub><italic>j</italic></sub>:</p>
<p>
<disp-formula id="disp-formula1-0272989X13480130">
<mml:math display="block" id="math1-0272989X13480130">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>R</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>~</mml:mo>
<mml:mtext>Poisson</mml:mtext>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>λ</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:msub>
<mml:mrow>
<mml:mi>N</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-0272989X13480130" xlink:href="10.1177_0272989X13480130-eq1.tif"/>
</disp-formula></p>
<p>
<disp-formula id="disp-formula2-0272989X13480130">
<mml:math display="block" id="math2-0272989X13480130">
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:mtext>exp</mml:mtext>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>λ</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>=</mml:mo>
<mml:mi>P</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mtext>adverse</mml:mtext>
<mml:mspace width="0.25em"/>
<mml:mtext>event</mml:mtext>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula2-0272989X13480130" xlink:href="10.1177_0272989X13480130-eq2.tif"/>
</disp-formula></p>
<p>Inferences are made about the difference in the rate of events λ<sub>1</sub>–λ<sub>2</sub> and the rate ratio λ<sub>1</sub>/λ<sub>2</sub>. Model 1 is estimated using WinBUGS, although similar results could be obtained from any standard statistical package.</p>
<fig id="fig1-0272989X13480130" position="float">
<label>Figure 1</label>
<caption>
<p>Structure of the decision tree for Model 1. DKA = diabetic ketoacidosis.</p>
</caption>
<graphic xlink:href="10.1177_0272989X13480130-fig1.tif"/>
</fig>
</sec>
<sec id="section6-0272989X13480130">
<title>Model 2</title>
<p>Model 2 uses a more complex structure(<xref ref-type="fig" rid="fig2-0272989X13480130">Figure 2</xref>) that relates all the available data (described in <xref ref-type="table" rid="table1-0272989X13480130">Table 1</xref>) as functions of parameters, making assumptions about the responses of patients to positive and negative test results and the effectiveness of remedial actions on preventing adverse events.</p>
<fig id="fig2-0272989X13480130" position="float">
<label>Figure 2</label>
<caption>
<p>Structure of the decision tree for Model 2. The structure for urine testing is the same as for blood testing. The pathways for “high glucose” and “no symptom” (normal day) branches have the same structure as for a “sick day.” The parameters for specificity and sensitivity depend on the ketone test strategy. The probabilities of taking the test depend on the test strategy and whether the patient is experiencing a sick day, high glucose reading, or normal day. Parameters <italic>a</italic> (<italic>p.sick)</italic> and <italic>b</italic> (<italic>p.gluc)</italic> (the probabilities of a sick day and high glucose readings); parameters <italic>f</italic> (<italic>p.s.ketone), g</italic> (<italic>p.g.ketone)</italic>, and <italic>h</italic> (<italic>p.oth.ketone)</italic> (the probabilities of high ketone levels on a sick day, after high glucose readings, or on a day without symptoms); the probability of DKA after a false negative <italic>(p.keta)</italic>, and the probability of hypoglycemia after a false positive <italic>(p.hypo)</italic> are assumed to be common to both blood and urine test strategies. <sup>#</sup>The value of the probability is the complement of the corresponding other branch. DKA = diabetic ketoacidosis.</p>
</caption>
<graphic xlink:href="10.1177_0272989X13480130-fig2.tif"/>
</fig>
<table-wrap id="table1-0272989X13480130" position="float">
<label>Table 1</label>
<caption>
<p>Data Used in the MPES, Predicted Values from Model 2, and Deviance</p>
</caption>
<graphic alternate-form-of="table1-0272989X13480130" xlink:href="10.1177_0272989X13480130-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Description of Parameter<hr/></th>
<th align="center" colspan="3">Data<hr/></th>
<th align="center">Parameter Name or Function of Parameters Estimated<hr/></th>
<th align="center" colspan="4">Results of Model 2 Estimated Using Full Data Set (Mean, 95% CI, and Deviance)<hr/></th>
<th align="center" colspan="4">Results of Model 2 Estimated Excluding Data Item 13 (Mean, 95% CI, and Deviance)<hr/></th>
</tr>
<tr>
<th align="left">Data No.</th>
<th align="center">Variables for Which There Were Directly Observed Data</th>
<th align="center">Numerator R</th>
<th align="center">Denominator N</th>
<th align="center">R/N</th>
<th align="center">P</th>
<th align="center">Predicted Probability</th>
<th align="center">2.5th Percentile</th>
<th align="center">97.5th Percentile</th>
<th align="center">Deviance</th>
<th align="center">Predicted Probability</th>
<th align="center">2.5th Percentile</th>
<th align="center">97.5th Percentile</th>
<th align="center">Deviance</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Probability of sick days</td>
<td>578</td>
<td>12,934</td>
<td>0.045</td>
<td><italic>p.sick</italic></td>
<td>0.045</td>
<td>0.041</td>
<td>0.048</td>
<td>0.994</td>
<td>0.044</td>
<td>0.041</td>
<td>0.048</td>
<td>1.029</td>
</tr>
<tr>
<td>2</td>
<td>Probability of high glucose days</td>
<td>3327</td>
<td>12,934</td>
<td>0.257</td>
<td><italic>p.gluc</italic></td>
<td>0.257</td>
<td>0.249</td>
<td>0.264</td>
<td>1.016</td>
<td>0.257</td>
<td>0.249</td>
<td>0.264</td>
<td>1.019</td>
</tr>
<tr>
<td>3</td>
<td>Take test on sick day (blood)</td>
<td>276</td>
<td>304</td>
<td>0.908</td>
<td><italic>p.s.comply.1</italic></td>
<td>0.905</td>
<td>0.869</td>
<td>0.935</td>
<td>0.978</td>
<td>0.905</td>
<td>0.870</td>
<td>0.935</td>
<td>0.975</td>
</tr>
<tr>
<td>4</td>
<td>Take test on glucose day (blood)</td>
<td>705</td>
<td>2089</td>
<td>0.337</td>
<td><italic>p.g.comply.1</italic></td>
<td>0.338</td>
<td>0.317</td>
<td>0.357</td>
<td>1.029</td>
<td>0.337</td>
<td>0.317</td>
<td>0.357</td>
<td>0.990</td>
</tr>
<tr>
<td>5</td>
<td>Take test on other day (blood)</td>
<td>885</td>
<td>4383</td>
<td>0.202</td>
<td><italic>p.oth.use.1</italic></td>
<td>0.202</td>
<td>0.189</td>
<td>0.214</td>
<td>1.030</td>
<td>0.202</td>
<td>0.190</td>
<td>0.214</td>
<td>0.980</td>
</tr>
<tr>
<td>6</td>
<td>Test positive if sick day (blood)</td>
<td>20</td>
<td>276</td>
<td>0.072</td>
<td><xref ref-type="disp-formula" rid="disp-formula3-0272989X13480130">Equation 3</xref></td>
<td>0.089</td>
<td>0.061</td>
<td>0.121</td>
<td>1.793</td>
<td>0.086</td>
<td>0.059</td>
<td>0.118</td>
<td>1.442</td>
</tr>
<tr>
<td>7</td>
<td>Test positive if high glucose (blood)</td>
<td>23</td>
<td>705</td>
<td>0.033</td>
<td><xref ref-type="disp-formula" rid="disp-formula4-0272989X13480130">Equation 4</xref></td>
<td>0.028</td>
<td>0.017</td>
<td>0.039</td>
<td>1.495</td>
<td>0.032</td>
<td>0.020</td>
<td>0.047</td>
<td>1.029</td>
</tr>
<tr>
<td>8</td>
<td>Test positive if normal (not sick day or high glucose) (blood)</td>
<td>0</td>
<td>885</td>
<td>0.000</td>
<td><xref ref-type="disp-formula" rid="disp-formula5-0272989X13480130">Equation 5</xref></td>
<td>0.002</td>
<td>0.143</td>
<td>0.005</td>
<td>3.335</td>
<td>0.001</td>
<td>0.113</td>
<td>0.005</td>
<td>2.939</td>
</tr>
<tr>
<td>9</td>
<td>Take test if sick day (urine)</td>
<td>168</td>
<td>274</td>
<td>0.613</td>
<td><italic>p.s.comply.2</italic></td>
<td>0.613</td>
<td>0.555</td>
<td>0.669</td>
<td>0.984</td>
<td>0.612</td>
<td>0.553</td>
<td>0.668</td>
<td>1.030</td>
</tr>
<tr>
<td>10</td>
<td>Take test if high glucose (urine)</td>
<td>432</td>
<td>1238</td>
<td>0.349</td>
<td><italic>p.g.comply.2</italic></td>
<td>0.349</td>
<td>0.322</td>
<td>0.375</td>
<td>0.978</td>
<td>0.349</td>
<td>0.322</td>
<td>0.376</td>
<td>0.982</td>
</tr>
<tr>
<td>11</td>
<td>Take test if not sick day or high glucose (urine)</td>
<td>1198</td>
<td>4646</td>
<td>0.258</td>
<td><italic>p.oth.use.2</italic></td>
<td>0.258</td>
<td>0.245</td>
<td>0.270</td>
<td>1.000</td>
<td>0.257</td>
<td>0.245</td>
<td>0.270</td>
<td>0.978</td>
</tr>
<tr>
<td>12</td>
<td>Test positive if sick day (urine)</td>
<td>26</td>
<td>168</td>
<td>0.155</td>
<td><xref ref-type="disp-formula" rid="disp-formula3-0272989X13480130">Equation 3</xref></td>
<td>0.117</td>
<td>0.088</td>
<td>0.147</td>
<td>2.835</td>
<td>0.123</td>
<td>0.095</td>
<td>0.154</td>
<td>1.834</td>
</tr>
<tr>
<td>13</td>
<td>Test positive if high glucose (urine)</td>
<td>18</td>
<td>432</td>
<td>0.042</td>
<td><xref ref-type="disp-formula" rid="disp-formula4-0272989X13480130">Equation 4</xref></td>
<td>0.065</td>
<td>0.053</td>
<td>0.078</td>
<td>4.581</td>
<td>0.076</td>
<td>0.060</td>
<td>0.094</td>
<td align="center">NA</td>
</tr>
<tr>
<td>14</td>
<td>Test positive if not sick day or high glucose (urine)</td>
<td>58</td>
<td>1198</td>
<td>0.048</td>
<td><xref ref-type="disp-formula" rid="disp-formula5-0272989X13480130">Equation 5</xref></td>
<td>0.044</td>
<td>0.034</td>
<td>0.054</td>
<td>1.477</td>
<td>0.049</td>
<td>0.037</td>
<td>0.062</td>
<td>1.033</td>
</tr>
<tr>
<td>15</td>
<td>All adverse events (blood) λ<sub>1</sub> (rate = events/patient-days)</td>
<td>11</td>
<td>10,638</td>
<td>0.001</td>
<td><xref ref-type="disp-formula" rid="disp-formula1-0272989X13480130">Equations 1</xref>, <xref ref-type="disp-formula" rid="disp-formula2-0272989X13480130">2</xref>, and <xref ref-type="disp-formula" rid="disp-formula12-0272989X13480130">12</xref></td>
<td>0.0010</td>
<td>0.551</td>
<td>0.001</td>
<td>0.802</td>
<td>0.001</td>
<td>0.562</td>
<td>0.001</td>
<td>0.835</td>
</tr>
<tr>
<td>16</td>
<td>All adverse events (urine) λ<sub>0</sub> (rate = events/patient-days)</td>
<td>22</td>
<td>10,910</td>
<td>0.002</td>
<td><xref ref-type="disp-formula" rid="disp-formula1-0272989X13480130">Equations 1</xref>, <xref ref-type="disp-formula" rid="disp-formula2-0272989X13480130">2</xref>, and <xref ref-type="disp-formula" rid="disp-formula12-0272989X13480130">12</xref></td>
<td>0.0022</td>
<td>0.001</td>
<td>0.003</td>
<td>0.965</td>
<td>0.002</td>
<td>0.001</td>
<td>0.003</td>
<td>0.975</td>
</tr>
<tr>
<td>17</td>
<td>False-positive rate (blood), Bektas<sup><xref ref-type="bibr" rid="bibr17-0272989X13480130">17</xref></sup>
</td>
<td>16</td>
<td>91</td>
<td>0.176</td>
<td><italic>fpr1,1</italic></td>
<td>0.172</td>
<td>0.109</td>
<td>0.245</td>
<td>0.797</td>
<td>0.172</td>
<td>0.109</td>
<td>0.245</td>
<td>0.812</td>
</tr>
<tr>
<td>18</td>
<td>False-positive rate (urine), Bektas<sup><xref ref-type="bibr" rid="bibr17-0272989X13480130">17</xref></sup>
</td>
<td>20</td>
<td>91</td>
<td>0.220</td>
<td><italic>fpr1,2</italic></td>
<td>0.218</td>
<td>0.146</td>
<td>0.299</td>
<td>0.826</td>
<td>0.219</td>
<td>0.148</td>
<td>0.300</td>
<td>0.834</td>
</tr>
<tr>
<td>19</td>
<td>Sensitivity (blood), Bektas<sup><xref ref-type="bibr" rid="bibr17-0272989X13480130">17</xref></sup>
</td>
<td>35</td>
<td>48</td>
<td>0.729</td>
<td><italic>Sens1,1</italic></td>
<td>0.729</td>
<td>0.617</td>
<td>0.827</td>
<td>0.700</td>
<td>0.730</td>
<td>0.619</td>
<td>0.825</td>
<td>0.702</td>
</tr>
<tr>
<td>20</td>
<td>Sensitivity (urine), Bektas<sup><xref ref-type="bibr" rid="bibr17-0272989X13480130">17</xref></sup>
</td>
<td>32</td>
<td>48</td>
<td>0.667</td>
<td><italic>Sens1,2</italic></td>
<td>0.667</td>
<td>0.549</td>
<td>0.774</td>
<td>0.743</td>
<td>0.667</td>
<td>0.550</td>
<td>0.774</td>
<td>0.724</td>
</tr>
<tr>
<td>21</td>
<td>False-positive rate (blood), Guerci<sup><xref ref-type="bibr" rid="bibr16-0272989X13480130">16</xref></sup>
</td>
<td>0</td>
<td>2</td>
<td>0.000</td>
<td><italic>fpr2,1</italic></td>
<td>0.038</td>
<td>0.000</td>
<td>0.217</td>
<td>0.165</td>
<td>0.033</td>
<td align="center">0,000</td>
<td>0.210</td>
<td>0.158</td>
</tr>
<tr>
<td>22</td>
<td>False-positive rate (urine), Guerci<sup><xref ref-type="bibr" rid="bibr16-0272989X13480130">16</xref></sup>
</td>
<td>0</td>
<td>2</td>
<td>0.000</td>
<td><italic>fpr2,2</italic></td>
<td>0.089</td>
<td>0.001</td>
<td>0.419</td>
<td>0.417</td>
<td>0.076</td>
<td align="center">0,000</td>
<td>0.401</td>
<td>0.396</td>
</tr>
<tr>
<td>23</td>
<td>Sensitivity (blood), Guerci<sup><xref ref-type="bibr" rid="bibr16-0272989X13480130">16</xref></sup>
</td>
<td>13</td>
<td>16</td>
<td>0.813</td>
<td><italic>sens2,1</italic></td>
<td>0.824</td>
<td>0.612</td>
<td>0.958</td>
<td>1.059</td>
<td>0.824</td>
<td>0.614</td>
<td>0.961</td>
<td>1.091</td>
</tr>
<tr>
<td>24</td>
<td>Sensitivity (urine), Guerci<sup><xref ref-type="bibr" rid="bibr16-0272989X13480130">16</xref></sup>
</td>
<td>10</td>
<td>16</td>
<td>0.625</td>
<td><italic>sens2,2</italic></td>
<td>0.632</td>
<td>0.394</td>
<td>0.841</td>
<td>1.011</td>
<td>0.632</td>
<td>0.393</td>
<td>0.838</td>
<td>1.012</td>
</tr>
<tr>
<th/>
<th align="center">Variables for Which There Were No Directly Observed Data</th>
<th/>
<th/>
<th/>
<th/>
<th align="center">Predicted Probability</th>
<th align="center">2.5th Percentile</th>
<th align="center">97.5th Percentile</th>
<th/>
<th align="center">Predicted probability</th>
<th align="center">2.5th Percentile</th>
<th align="center">97.5th Percentile</th>
<th/>
</tr>
<tr>
<td/>
<td>False-positive rate of blood test, RCT</td>
<td/>
<td/>
<td/>
<td><italic>Fpr3,1</italic></td>
<td>0.0007</td>
<td>0.000</td>
<td>0.004</td>
<td/>
<td>0.0005</td>
<td>0.000</td>
<td>0.003</td>
<td/>
</tr>
<tr>
<td/>
<td>False-positive rate of urine test, RCT</td>
<td/>
<td/>
<td/>
<td><italic>Fpr3,2</italic></td>
<td>0.042</td>
<td>0.032</td>
<td>0.053</td>
<td/>
<td>0.047</td>
<td>0.035</td>
<td>0.061</td>
<td/>
</tr>
<tr>
<td/>
<td>Sensitivity of blood test, RCT</td>
<td/>
<td/>
<td/>
<td><italic>Sens3,1</italic></td>
<td>0.997</td>
<td>0.978</td>
<td>1.000</td>
<td/>
<td>0.998</td>
<td>0.990</td>
<td>1.000</td>
<td/>
</tr>
<tr>
<td/>
<td>Sensitivity of urine test, RCT</td>
<td/>
<td/>
<td/>
<td><italic>Sens3,2</italic></td>
<td>0.875</td>
<td>0.576</td>
<td>0.998</td>
<td/>
<td>0.922</td>
<td>0.698</td>
<td>1.000</td>
<td/>
</tr>
<tr>
<td/>
<td>Probability of high ketone on a sick day</td>
<td/>
<td/>
<td/>
<td><italic>p.s.ketone</italic></td>
<td>0.088</td>
<td>0.060</td>
<td>0.120</td>
<td/>
<td>0.086</td>
<td>0.059</td>
<td>0.117</td>
<td/>
</tr>
<tr>
<td/>
<td>Probability of high ketone with high glucose levels</td>
<td/>
<td/>
<td/>
<td><italic>p.g.ketone</italic></td>
<td>0.026</td>
<td>0.016</td>
<td>0.038</td>
<td/>
<td>0.032</td>
<td>0.020</td>
<td>0.046</td>
<td/>
</tr>
<tr>
<td/>
<td>Probability of high ketone on a normal day</td>
<td/>
<td/>
<td/>
<td><italic>p.oth.ketone</italic></td>
<td>0.001</td>
<td>0.000</td>
<td>0.004</td>
<td/>
<td>0.001</td>
<td>0.028</td>
<td>0.004</td>
<td/>
</tr>
<tr>
<th/>
<th/>
<th align="center" colspan="3"/>
<th align="center">Parameter Name or Function of Parameters Estimated<hr/></th>
<th align="center" colspan="4"/>
<th align="center" colspan="4"/>
</tr>
<tr>
<th/>
<th align="center">Variables for Which There Were No Directly Observed Data</th>
<th/>
<th/>
<th/>
<th align="center">P</th>
<th align="center">Predicted Probability</th>
<th align="center">2.5th Percentile</th>
<th align="center">97.5th Percentile</th>
<th/>
<th align="center">Predicted probability</th>
<th align="center">2.5th Percentile</th>
<th align="center">97.5th Percentile</th>
<th/>
</tr>
<tr>
<td/>
<td>Probability of DKA, given high ketone and no preventive self-medication</td>
<td/>
<td/>
<td/>
<td><italic>p.keta</italic></td>
<td>0.189</td>
<td>0.084</td>
<td>0.337</td>
<td/>
<td>0.166</td>
<td>0.076</td>
<td>0.299</td>
<td/>
</tr>
<tr>
<td/>
<td>Probability of hypoglycemia, given normal ketone but inappropriate self-medication</td>
<td/>
<td/>
<td/>
<td><italic>p.hypo</italic></td>
<td>0.071</td>
<td>0.005</td>
<td>0.171</td>
<td/>
<td>0.067</td>
<td>0.006</td>
<td>0.153</td>
<td/>
</tr>
<tr>
<td/>
<td>Mean log-diagnostic odds ratio of blood test</td>
<td/>
<td/>
<td/>
<td><italic>Mu.alpha1</italic></td>
<td>8.62</td>
<td>0.57</td>
<td>18.17</td>
<td/>
<td>19.81</td>
<td>−9.12</td>
<td>69.24</td>
<td/>
</tr>
<tr>
<td/>
<td>Mean log-diagnostic odds ratio of urine test</td>
<td/>
<td/>
<td/>
<td><italic>Mu.alpha2</italic></td>
<td>4.13</td>
<td>−3.51</td>
<td>12.67</td>
<td/>
<td>10.19</td>
<td>−22.3</td>
<td>50.35</td>
<td/>
</tr>
<tr>
<td/>
<td>Between-study SD of log-DOR</td>
<td/>
<td/>
<td/>
<td><italic>Sd.alpha</italic></td>
<td>14.9</td>
<td>3.19</td>
<td>59.14</td>
<td/>
<td>19.56</td>
<td>3.63</td>
<td>70.23</td>
<td/>
</tr>
<tr>
<td/>
<td>Mean diagnostic threshold parameter</td>
<td/>
<td/>
<td/>
<td><italic>Mu.theta</italic></td>
<td>−0.80</td>
<td>−5.46</td>
<td>3.00</td>
<td/>
<td>−1.22</td>
<td>−31.89</td>
<td>30.52</td>
<td/>
</tr>
<tr>
<td/>
<td>Between-study SD of threshold</td>
<td/>
<td/>
<td/>
<td><italic>Sd.theta</italic></td>
<td>8.07</td>
<td>0.07</td>
<td>50.23</td>
<td/>
<td>12.22</td>
<td>0.11</td>
<td>68.12</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0272989X13480130">
<p>Note: All data are from Laffel and others<sup><xref ref-type="bibr" rid="bibr14-0272989X13480130">14</xref></sup> unless specified otherwise. False-positive rate = 1-specificity. CI = confidence interval; DKA = diabetic ketoacidosis; DOR = diagnostic odds ratios; RCT = randomized controlled trial; SD = standard deviation.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>As with Model 1, the RCT data on the number of adverse events are modeled by a Poisson distribution (<xref ref-type="disp-formula" rid="disp-formula1-0272989X13480130">Equations 1</xref> and <xref ref-type="disp-formula" rid="disp-formula2-0272989X13480130">2</xref>). These data are then related in the model to other variables such as the performance of the tests (the unobserved sensitivity and specificity of the tests as used in the RCT), the probability of high ketone levels in this population (also unobserved), the probability of positive test results (observed in the RCT), and the probability of compliance by patients with the test protocol (observed in the RCT).</p>
</sec>
</sec>
<sec id="section7-0272989X13480130">
<title>Test Protocol</title>
<p>The protocol for use of each system is similar.<sup><xref ref-type="bibr" rid="bibr14-0272989X13480130">14</xref></sup> Young people with Type 1 diabetes are expected to test their ketone levels if they experience symptoms of ketosis, such as nausea or abdominal pain on a sick day (that occurs in any day with probability <italic>p.sick</italic>), or have 2 high successive glucose readings (probability <italic>p.gluc</italic>). Parameters <italic>p.sick</italic> and <italic>p.gluc</italic> are assumed independent of the testing strategy and therefore equal in both groups in the RCT. It is also assumed that the probabilities of sick days and/or high glucose levels are independent in any individual from one day to the next. Patients do not always follow the protocol, however. Only a proportion of patients use the test on sick days or following high glucose readings (probabilities <italic>p.s.comply.1</italic> and <italic>p.g.comply.1</italic> in the blood ketone group and <italic>p.s.comply.2</italic> and <italic>p.g.comply.2</italic> in the urine ketone group), and some patients use the test on days when they do not have symptoms (probability <italic>p.oth.use.1</italic> in the blood ketone group and <italic>p.oth.use.2</italic> in the urine ketone group).</p>
<p>A positive ketone test result indicates high ketone levels and a risk of DKA, and patients should consider remedial action, which might include injection of short-acting insulin. No further action is assumed to be taken given a negative reading, indicating normal ketone levels.</p>
<p>The prevalence of high ketone levels on sick days, after high glucose readings, and on other days is expressed as probabilities <italic>p.s.ketone, p.g.ketone</italic>, and <italic>p.oth.ketone</italic>, assumed independent of the testing strategy. There is no direct evidence on these parameters, but their values can be estimated indirectly by information on functions of these parameters, as long as there are data on at least as many functions as parameters.</p>
</sec>
<sec id="section8-0272989X13480130">
<title>Frequency of Sick Days, High Glucose Days, and Positive Test Results</title>
<p>The frequency of sick days, high glucose days, and normal days; the frequency with which patients use the tests on these days; and the frequency of positive test results on these days are random variables (denominated by vector <bold><italic>R</italic></bold>) generated by binomial distribution with denominator <bold><italic>N</italic></bold> (number of patients at risk) and probability <bold><italic>P</italic></bold> (<xref ref-type="table" rid="table1-0272989X13480130">Table 1</xref>). As well as the direct evidence, there is also indirect evidence from the RCT on the probability of a positive test result in each strategy expressed as a function of other parameters (<xref ref-type="disp-formula" rid="disp-formula3-0272989X13480130">Equations 3</xref>, <xref ref-type="disp-formula" rid="disp-formula4-0272989X13480130">4</xref>, and <xref ref-type="disp-formula" rid="disp-formula5-0272989X13480130">5</xref>). The probability of a positive test result if the patient is tested for ketones on a sick day <italic>P(T+ |sick day)<sub>j</sub></italic> equals the true positives plus the false positives in group <italic>j</italic>. The probability of a true positive is the probability the patient has high ketones <italic>(p.s.ketone)</italic> multiplied by the sensitivity of the test in the RCT population <italic>(sens.3<sub>j</sub>).</italic> The index number 3 is used for this parameter in the RCT to distinguish it from sensitivity estimated in the other 2 studies. It is assumed that the RCT sample correctly represents the target population. The probability of a false positive is the probability the patient does not have high ketones <italic>(</italic>1<italic>-p.s.ketone)</italic> multiplied by the false-positive rate <italic>(</italic>1<italic>-spec.3<sub>j</sub>)</italic> in the RCT population. There are no direct data on parameters <italic>spec.3<sub>j</sub></italic> or <italic>sens.3<sub>j</sub></italic>, and their values are estimated indirectly by the MPES (see section Sensitivity and Specificity).</p>
<p>
<disp-formula id="disp-formula3-0272989X13480130">
<mml:math display="block" id="math3-0272989X13480130">
<mml:mrow>
<mml:mi>P</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>+</mml:mo>
<mml:mo stretchy="false">|</mml:mo>
<mml:mi>s</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>k</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>d</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>y</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>s</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>k</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>e</mml:mi>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>s</mml:mi>
<mml:mo>.</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mn>3</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mtext>-</mml:mtext>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>s</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>k</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>e</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mtext>-</mml:mtext>
<mml:mi>s</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>c</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mo>.</mml:mo>
<mml:mn>3</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula3-0272989X13480130" xlink:href="10.1177_0272989X13480130-eq3.tif"/>
</disp-formula></p>
<p>
<disp-formula id="disp-formula4-0272989X13480130">
<mml:math display="block" id="math4-0272989X13480130">
<mml:mrow>
<mml:mi>P</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>+</mml:mo>
<mml:mo stretchy="false">|</mml:mo>
<mml:mi>h</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>g</mml:mi>
<mml:mi>h</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>g</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>r</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>d</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>g</mml:mi>
<mml:mi>s</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>g</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>k</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>e</mml:mi>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>s</mml:mi>
<mml:mo>.</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mn>3</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mtext>-</mml:mtext>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>g</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>k</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>e</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mtext>-</mml:mtext>
<mml:mi>s</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>c</mml:mi>
<mml:mo>.</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mn>3</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula4-0272989X13480130" xlink:href="10.1177_0272989X13480130-eq4.tif"/>
</disp-formula></p>
<p>
<disp-formula id="disp-formula5-0272989X13480130">
<mml:math display="block" id="math5-0272989X13480130">
<mml:mrow>
<mml:mi>P</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>+</mml:mo>
<mml:mo stretchy="false">|</mml:mo>
<mml:mi>n</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>m</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>l</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>d</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>y</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>o</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>h</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>k</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>e</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mo>*</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>s</mml:mi>
<mml:mo>.</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mn>3</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mtext>-</mml:mtext>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>o</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>h</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>k</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>e</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mtext>-</mml:mtext>
<mml:mi>s</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>c</mml:mi>
<mml:mo>.</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mn>3</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula5-0272989X13480130" xlink:href="10.1177_0272989X13480130-eq5.tif"/>
</disp-formula>
</p>
<p>A false negative implies the patient has high ketone levels but is unaware of this. This can occur if the patient takes the test and the test wrongly reports normal ketone levels, or if the patient does not take the test. The probability of a false-negative test result or unknowingly having high ketones in group <italic>j</italic> is given by <xref ref-type="disp-formula" rid="disp-formula6-0272989X13480130">Equations 6</xref><xref ref-type="disp-formula" rid="disp-formula7-0272989X13480130"/><xref ref-type="disp-formula" rid="disp-formula8-0272989X13480130"/><xref ref-type="disp-formula" rid="disp-formula9-0272989X13480130"/><xref ref-type="disp-formula" rid="disp-formula10-0272989X13480130"/>–<xref ref-type="disp-formula" rid="disp-formula11-0272989X13480130">11</xref>:</p>
<p>
<disp-formula id="disp-formula6-0272989X13480130">
<mml:math display="block" id="math6-0272989X13480130">
<mml:mrow>
<mml:mi>P</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>f</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>n</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>g</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>v</mml:mi>
<mml:mi>e</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>s</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>k</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>d</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>y</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>s</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>k</mml:mi>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>s</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>k</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>e</mml:mi>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>s</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>c</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>m</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>y</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>j</mml:mi>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mtext>-</mml:mtext>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>s</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mo>.</mml:mo>
<mml:mn>3</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>+</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mtext>-</mml:mtext>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>s</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>c</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>m</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>y</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>j</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>]</mml:mo>
</mml:mrow>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula6-0272989X13480130" xlink:href="10.1177_0272989X13480130-eq6.tif"/>
</disp-formula></p>
<p>
<disp-formula id="disp-formula7-0272989X13480130">
<mml:math display="block" id="math7-0272989X13480130">
<mml:mrow>
<mml:mi>P</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>f</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>n</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>g</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>v</mml:mi>
<mml:mi>e</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>h</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>g</mml:mi>
<mml:mi>h</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>g</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>g</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>c</mml:mi>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>g</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>k</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>e</mml:mi>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>g</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>c</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>m</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>y</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>j</mml:mi>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mtext>-</mml:mtext>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>s</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mo>.</mml:mo>
<mml:mn>3</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>+</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mtext>-</mml:mtext>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>g</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>c</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>m</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>y</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>j</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>]</mml:mo>
</mml:mrow>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula7-0272989X13480130" xlink:href="10.1177_0272989X13480130-eq7.tif"/>
</disp-formula>
</p>
<p>
<disp-formula id="disp-formula8-0272989X13480130">
<mml:math display="block" id="math8-0272989X13480130">
<mml:mrow>
<mml:mi>P</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>f</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>n</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>g</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>v</mml:mi>
<mml:mi>e</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>o</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>h</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>r</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>d</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>y</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mtext>-</mml:mtext>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>s</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>k</mml:mi>
<mml:mtext>-</mml:mtext>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>g</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>c</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>o</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>h</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>k</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>e</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mtext>-</mml:mtext>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>s</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mo>.</mml:mo>
<mml:mn>3</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mspace width="0.25em"/>
<mml:mo>+</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mtext>-</mml:mtext>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>o</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>h</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>u</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>j</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>]</mml:mo>
</mml:mrow>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula8-0272989X13480130" xlink:href="10.1177_0272989X13480130-eq8.tif"/>
</disp-formula>
</p>
<p>A false positive implies the patient wrongly believes he or she has high ketone levels. The probability of a false positive in group <italic>j</italic> is as follows:</p>
<p>
<disp-formula id="disp-formula9-0272989X13480130">
<mml:math display="block" id="math9-0272989X13480130">
<mml:mrow>
<mml:mi>P</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>f</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>v</mml:mi>
<mml:mi>e</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>s</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>k</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>d</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>y</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>s</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>k</mml:mi>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>s</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>c</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>m</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>y</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>j</mml:mi>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mtext>-</mml:mtext>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>s</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>k</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>e</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mtext>-</mml:mtext>
<mml:mi>s</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>c</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mo>.</mml:mo>
<mml:mn>3</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula9-0272989X13480130" xlink:href="10.1177_0272989X13480130-eq9.tif"/>
</disp-formula>
</p>
<p>
<disp-formula id="disp-formula10-0272989X13480130">
<mml:math display="block" id="math10-0272989X13480130">
<mml:mrow>
<mml:mi>P</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mi>f</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>v</mml:mi>
<mml:mi>e</mml:mi>
<mml:mo>,</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>h</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>g</mml:mi>
<mml:mi>h</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>g</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>cos</mml:mi>
<mml:mi>e</mml:mi>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mi>j</mml:mi>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>g</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>c</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mo>*</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>g</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>c</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>m</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>y</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>j</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mo>*</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>g</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>k</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>e</mml:mi>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>*</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:mi>s</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>c</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mo>.</mml:mo>
<mml:mn>3</mml:mn>
</mml:mrow>
<mml:mi>j</mml:mi>
</mml:msub>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula10-0272989X13480130" xlink:href="10.1177_0272989X13480130-eq10.tif"/>
</disp-formula>
</p>
<p>
<disp-formula id="disp-formula11-0272989X13480130">
<mml:math display="block" id="math11-0272989X13480130">
<mml:mrow>
<mml:mi>P</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>f</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>v</mml:mi>
<mml:mi>e</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>o</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>h</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>r</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>d</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>y</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mtext>-</mml:mtext>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>s</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>k</mml:mi>
<mml:mtext>-</mml:mtext>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>g</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>c</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>o</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>h</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>u</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>j</mml:mi>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mtext>-</mml:mtext>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>o</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>h</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>k</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>e</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mtext>-</mml:mtext>
<mml:mi>s</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>c</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mo>.</mml:mo>
<mml:mn>3</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula11-0272989X13480130" xlink:href="10.1177_0272989X13480130-eq11.tif"/>
</disp-formula>
</p>
<p>The overall probability of a false negative <italic>P(false negative)<sub>j</sub></italic> is the sum of the probabilities of a false negative on a sick day, on a high glucose day, or on a normal day. A false negative, or not taking the test when indicated, runs the risk that the patient will take inadequate preventive action, which could lead to DKA with conditional probability <italic>p.keta</italic>. The overall probability of a false positive <italic>P(false positive)<sub>j</sub></italic> is the sum of the probabilities of a false positive on a sick day, on a high glucose day, or on a normal day. A false positive runs the risk of the patient taking inappropriate corrective action (which might include self-administering additional insulin when this is not required), which could lead to hypoglycemia with conditional probability <italic>p.hypo</italic>. Both types of adverse event require urgent medical attention and possibly hospitalization. It is assumed that a correct positive test result allows successful preventive action to be taken without medical attention and ketone levels return to normal on the same day. There are no direct data on <italic>p.keta</italic> or <italic>p.hypo</italic>, and they are given uninformative beta(1,1) prior distributions and estimated by the MPES.</p>
</sec>
<sec id="section9-0272989X13480130">
<title>Rate of Adverse Events Requiring Medical Attention</title>
<p>The probability of an adverse event (DKA or a hypoglycemia) requiring medical attention in group <italic>j</italic> in a day is related to the probability of a false-negative result and a false-positive result by the following expression:</p>
<p>
<disp-formula id="disp-formula12-0272989X13480130">
<mml:math display="block" id="math12-0272989X13480130">
<mml:mrow>
<mml:mi>P</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>a</mml:mi>
<mml:mi>d</mml:mi>
<mml:mi>v</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>e</mml:mi>
<mml:mi>v</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>t</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>P</mml:mi>
<mml:msup>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>f</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>n</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>g</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>v</mml:mi>
<mml:mi>e</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>k</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>a</mml:mi>
<mml:mo>+</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>P</mml:mi>
<mml:msup>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>f</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>v</mml:mi>
<mml:mi>e</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>h</mml:mi>
<mml:mi>y</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>o</mml:mi>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula12-0272989X13480130" xlink:href="10.1177_0272989X13480130-eq12.tif"/>
</disp-formula>
</p>
<p>Thus, the parameter <italic>P(adverse event)<sub>j</sub></italic> is informed by 2 equations: directly from the RCT outcomes by <xref ref-type="disp-formula" rid="disp-formula2-0272989X13480130">Equation 2</xref> and indirectly by <xref ref-type="disp-formula" rid="disp-formula12-0272989X13480130">Equation 12</xref>.</p>
</sec>
<sec id="section10-0272989X13480130">
<title>Sensitivity and Specificity</title>
<p>There was direct or indirect evidence informing the sensitivity (parameters <italic>sens<sub>ij</sub></italic>) and specificity (parameters <italic>spec<sub>ij</sub></italic>) from 3 studies <italic>i</italic> = 1,2,3 in the 2 tests <italic>j</italic> = 1:blood and <italic>j</italic> = 2:urine. Bektas and others<sup><xref ref-type="bibr" rid="bibr17-0272989X13480130">17</xref></sup> (study <italic>i</italic> = 1) and Guerci and others<sup><xref ref-type="bibr" rid="bibr16-0272989X13480130">16</xref></sup> (study <italic>i</italic> = 2) estimated sensitivity by giving both the urine and the blood ketone test to a sample of patients who were known to have high ketone levels. Similarly, specificity was estimated in these 2 studies by giving both the urine test and blood test to an independent sample of patients who were known to have normal ketone levels. Bektas and others (study <italic>i</italic> = 1) administered the tests in the emergency department of a hospital. Guerci and others (study <italic>i</italic> = 2) administered the tests in Type 1 diabetic patients a short while after interruption of subcutaneous insulin infusion. Study <italic>i</italic> = 3 is the RCT (Laffel and others<sup><xref ref-type="bibr" rid="bibr14-0272989X13480130">14</xref></sup>). No direct data are available to inform sensitivity and specificity from the RCT, and these parameters are estimated indirectly by the MPES.</p>
<p>The sensitivity and specificity for each test in each study may be correlated because both are functions of the diagnostic threshold used for identifying a positive test result.<sup><xref ref-type="bibr" rid="bibr6-0272989X13480130">6</xref></sup> This dependency is represented by a receiver operator characteristic (ROC) curve for each test in each study.</p>
<p>For study <italic>i</italic> = 1 … 3, test <italic>j</italic> = 1:blood test and <italic>j</italic> = 2:urine test.</p>
<p>
<disp-formula id="disp-formula13-0272989X13480130">
<mml:math display="block" id="math13-0272989X13480130">
<mml:mrow>
<mml:mi>F</mml:mi>
<mml:mi>P</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>R</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mn>1</mml:mn>
<mml:mtext>-</mml:mtext>
<mml:mi>s</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>e</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>c</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula13-0272989X13480130" xlink:href="10.1177_0272989X13480130-eq13.tif"/>
</disp-formula>
</p>
<p>
<disp-formula id="disp-formula14-0272989X13480130">
<mml:math display="block" id="math14-0272989X13480130">
<mml:mrow>
<mml:mi>L</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>g</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>t</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>n</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>s</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mspace width="0.25em"/>
<mml:mo>=</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>e</mml:mi>
<mml:mi>x</mml:mi>
<mml:mi>p</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mi>h</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>t</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>5</mml:mn>
<mml:mspace width="0.25em"/>
<mml:mi>a</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>h</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula14-0272989X13480130" xlink:href="10.1177_0272989X13480130-eq14.tif"/>
</disp-formula>
</p>
<p>
<disp-formula id="disp-formula15-0272989X13480130">
<mml:math display="block" id="math15-0272989X13480130">
<mml:mrow>
<mml:mi>L</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>g</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>t</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>F</mml:mi>
<mml:mi>P</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>R</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mspace width="0.25em"/>
<mml:mo>=</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>e</mml:mi>
<mml:mi>x</mml:mi>
<mml:mi>p</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mi>h</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>t</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>5</mml:mn>
<mml:mspace width="0.25em"/>
<mml:mi>a</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>h</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula15-0272989X13480130" xlink:href="10.1177_0272989X13480130-eq15.tif"/>
</disp-formula>
</p>
<p>Parameters <italic>theta<sub>i</sub></italic> can be interpreted as the diagnostic thresholds for positive test results in each study <italic>i</italic> and are assumed to be random effects with a common mean <italic>mu.theta</italic> and standard deviation <italic>sd.theta</italic>. Parameters <italic>alpha<sub>i</sub></italic><sub>1</sub> and <italic>alpha<sub>i</sub></italic><sub>2</sub> can be interpreted as the discriminatory power of the tests to distinguish true positives from false positives in test <italic>j</italic> = 1 and test <italic>j</italic> = 2, or the log diagnostic odds ratios (DOR) of the tests. These variables are also assumed random effects with means <italic>mu.alpha<sub>j</sub></italic> and common standard deviation <italic>sd.alpha</italic>. The values of the sensitivity and specificity in each study <italic>i</italic> = 1 … 3 are assumed to be drawn at random from a common ROC. Parameters <italic>mu.alpha<sub>j</sub></italic> and <italic>mu.theta</italic> were given uninformative normal N(0,0.0001) priors, and probabilities were assigned uninformative beta(1,1) priors. Alternative model specifications were tested. In a “common treatment effect” model, the difference in the DOR between the tests was assumed the same for all studies. In an “independent effects” model, the difference in the DOR between the tests was assumed to be independent for each study. All models assume that the ROC curves are symmetrical, that is, the DOR for each test does not vary with the diagnostic threshold.<sup><xref ref-type="bibr" rid="bibr6-0272989X13480130">6</xref></sup> The base-case model used gamma(0.001,0.001) priors for the between-study precision parameters (defined as 1/<italic>sd</italic><sup>2</sup>). Uniform (0,10) priors for the standard deviations <italic>sd.theta</italic> and <italic>sd.alpha</italic> were used in a sensitivity analysis.</p>
</sec>
<sec id="section11-0272989X13480130">
<title>Costs</title>
<p>Although the primary focus of this article is to estimate the effectiveness of the technologies, it is straightforward to also calculate the costs. The perspective is the National Health Service of Spain. The acquisition cost per test is €2.55 for the blood monitoring method (personal communication, Purchasing Department, Abbott Laboratories, Madrid, Spain, 20 November 2008; unreferenced) and €0.23 for the urine strips.<sup><xref ref-type="bibr" rid="bibr18-0272989X13480130">18</xref></sup> The cost to the health service of treating an adverse event is €507 for an inpatient stay and €157 for a visit to the emergency room.<sup><xref ref-type="bibr" rid="bibr19-0272989X13480130">19</xref></sup> The RCT found that one-third of adverse events requiring medical attention were treated as an inpatient stay and the remainder were treated in the emergency room.<sup><xref ref-type="bibr" rid="bibr14-0272989X13480130">14</xref></sup> Hence the average cost of an adverse event is estimated to be 1/3 × 507 + 2/3 × 157 = €274.<sup><xref ref-type="bibr" rid="bibr12-0272989X13480130">12</xref></sup> The average cost per day of treatment of adverse events plus test consumables is as follows:</p>
<p>
<disp-formula id="disp-formula16-0272989X13480130">
<mml:math display="block" id="math16-0272989X13480130">
<mml:mrow>
<mml:mtext>In the blood group</mml:mtext>
<mml:mo>:</mml:mo>
<mml:mi>P</mml:mi>
<mml:msup>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>a</mml:mi>
<mml:mi>d</mml:mi>
<mml:mi>v</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>e</mml:mi>
<mml:mi>v</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>t</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mn>274</mml:mn>
<mml:mo>+</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>s</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>s</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>c</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>m</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>y</mml:mi>
<mml:mo>.</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>+</mml:mo>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>g</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>c</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>g</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>c</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>m</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>y</mml:mi>
<mml:mo>.</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>+</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mtext>-</mml:mtext>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>s</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>k</mml:mi>
<mml:mtext>-</mml:mtext>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>g</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>c</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>o</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>h</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>u</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mo>.</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mn>2</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>55</mml:mn>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula16-0272989X13480130" xlink:href="10.1177_0272989X13480130-eq16.tif"/>
</disp-formula>
</p>
<p>
<disp-formula id="disp-formula17-0272989X13480130">
<mml:math display="block" id="math17-0272989X13480130">
<mml:mrow>
<mml:mtext>In the urine group</mml:mtext>
<mml:mo>:</mml:mo>
<mml:mi>P</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>a</mml:mi>
<mml:mi>d</mml:mi>
<mml:mi>v</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>e</mml:mi>
<mml:mi>v</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>t</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msub>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mn>274</mml:mn>
<mml:mo>+</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>s</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>k</mml:mi>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>s</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>c</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>m</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>y</mml:mi>
<mml:mo>.</mml:mo>
<mml:mn>2</mml:mn>
<mml:mo>+</mml:mo>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>g</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>c</mml:mi>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>g</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>c</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>m</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>y</mml:mi>
<mml:mo>.</mml:mo>
<mml:mn>2</mml:mn>
<mml:mo>+</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mtext>-</mml:mtext>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>s</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>c</mml:mi>
<mml:mi>k</mml:mi>
<mml:mtext>-</mml:mtext>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>g</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>c</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mi>p</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>o</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>h</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>u</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mo>.</mml:mo>
<mml:mn>2</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mspace width="0.25em"/>
<mml:mspace width="0.25em"/>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>23</mml:mn>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula17-0272989X13480130" xlink:href="10.1177_0272989X13480130-eq17.tif"/>
</disp-formula>
</p>
</sec>
<sec id="section12-0272989X13480130">
<title>Model Checking and Diagnostics</title>
<p>The MCMC was carried out in WinBUGS v1.4.3 with 15,000 simulations and a burn-in of 5000 simulations. Convergence was checked by running 2 chains simultaneously.</p>
<p>The overall goodness of fit of each model was assessed using the deviance information criterion (DIC) and the posterior mean deviance.<sup><xref ref-type="bibr" rid="bibr20-0272989X13480130">20</xref></sup> The consistency of individual data points was assessed using the deviance contribution.<sup><xref ref-type="bibr" rid="bibr5-0272989X13480130">5</xref></sup> The DIC is the log-likelihood of the model less the log-likelihood of the saturated model, multiplied by −2. The posterior mean deviance is calculated as the sum of the deviance contributions of the individual data points, and its value should be approximately equal to the number of data points in a consistent model.<sup><xref ref-type="bibr" rid="bibr5-0272989X13480130">5</xref></sup> The full WinBUGS code for Model 2 is shown in the <xref ref-type="app" rid="app1-0272989X13480130">Appendix</xref>.</p>
</sec>
<sec id="section13-0272989X13480130">
<title>Sensitivity Analyses</title>
<p>One of the advantages of using MPES is that it often allows a richer set of sensitivity analyses to be undertaken than would be possible in a conventional model. In this illustration, one can ask to what extent the reduction in adverse events in the blood test strategy in the RCT is attributable to the improved test performance and to what extent it is attributable to improved patient compliance with the test protocol. To examine this question, a sensitivity analysis is conducted by estimating what the impact on adverse events and costs would have been if compliance had been the same in both groups and the test strategies only differed in test accuracy.</p>
</sec>
</sec>
<sec id="section14-0272989X13480130" sec-type="results">
<title>Results</title>
<sec id="section15-0272989X13480130">
<title>Model 1</title>
<p>Model 1 estimated that the difference in the probability of an adverse event between the 2 strategies was 0.0011 (95% confidence interval [CI] 0.000003–0.00216) per day (11 per 10,000 patients), or a rate ratio of 0.53 for blood ketone v. urine ketone (95% CI 0.24–0.99). The number of data points (2) is equal to the number of parameters, and therefore model consistency and deviance are not meaningful measures. This simple model serves as a point of reference to compare with the results of the MPES (Model 2).</p>
</sec>
<sec id="section16-0272989X13480130">
<title>Model 2</title>
<p><xref ref-type="table" rid="table1-0272989X13480130">Table 1</xref> shows the mean and 95% percentiles of each parameter estimated by the MPES using Model 2 and provides point-by-point model checking information. The predicted difference in the probability of an adverse event between the 2 strategies was 0.0012 per day (95% CI 0.0005–0.00229), rate ratio 0.481 (0.224–0.757), very similar to the expected values in Model 1. The confidence interval for the rate ratio in adverse events is slightly narrower, perhaps partly reflecting the greater amount of data in Model 2 and partly due to the structural assumptions in the model that may eliminate some “noise.” However, whereas Model 1 is entirely focused on the outcomes, Model 2 also estimates variables related to the process of the testing strategies, including probabilities of compliance with test protocol and the probability of test positives. Model 2 also estimates variables that are not directly informed by any data, in particular, the probabilities of high ketone levels given symptoms or not, the accuracy (specificity and sensitivity) of the tests in the RCT setting (<xref ref-type="table" rid="table1-0272989X13480130">Table 1</xref>), the probability of DKA following a false-positive test result, and the probability of hypoglycemia following a false negative. The summary ROC shows that blood monitoring of ketones is predicted to be more accurate than urine monitoring (shown by a greater area under the ROC curve) (<xref ref-type="fig" rid="fig3-0272989X13480130">Figure 3</xref>). The model predictions of the sensitivity and specificity of the tests are “shrunk” toward the mean (i.e., the summary ROC for each test), showing how the random effects model uses the assumption that parameters belong to a common distribution (borrow strength across studies) to improve predictions.<sup><xref ref-type="bibr" rid="bibr9-0272989X13480130">9</xref></sup> The shrinkage is greater for the smaller study (Guerci and others<sup><xref ref-type="bibr" rid="bibr16-0272989X13480130">16</xref></sup>). There are no direct data on sensitivity and specificity from the RCT, and predictions are based on the functions of parameters estimated by the MPES. The estimated difference in costs was €0.290 per person per day (95% CI 0.002–0.302).</p>
<fig id="fig3-0272989X13480130" position="float">
<label>Figure 3</label>
<caption>
<p>Predicted summary receiver operator curve for each test, data for Guerci and others and Bektas and others, and model predictions of mean sensitivity and false positive rate for each study (Guerci and others,<sup><xref ref-type="bibr" rid="bibr16-0272989X13480130">16</xref></sup> Bektas and others,<sup><xref ref-type="bibr" rid="bibr17-0272989X13480130">17</xref></sup> and Laffel and others<sup><xref ref-type="bibr" rid="bibr14-0272989X13480130">14</xref></sup>).</p>
</caption>
<graphic xlink:href="10.1177_0272989X13480130-fig3.tif"/>
</fig>
</sec>
<sec id="section17-0272989X13480130">
<title>Goodness of Fit</title>
<p>The value of the deviance is greater than 2 for 3 of the data points in Model 2. These were point 8, the probability of testing positive for ketones on a “normal” day using the blood test strategy; point 12, the probability of testing positive on a sick day using the urine test strategy; and point 13, the probability of testing positive for ketones on a high glucose day using the urine strategy. In all 3 cases, the observed data were outside the 95% confidence intervals for the estimated parameters.</p>
</sec>
<sec id="section18-0272989X13480130">
<title>Model Validation and Checking</title>
<p>Analyses were carried out to investigate which data points were inconsistent with the others. The model was reestimated with each of the 3 deviant data points left out in turn, and the results were compared with the original 24-item data set. If item 8 or item 12 is removed, the model fails to converge. If item 13 is removed, the model converges on a stable solution with parameter estimates in most cases similar to the full data set. However, the sum of the deviances is lower (23.8 compared with 23 data points), indicating improved consistency (<xref ref-type="table" rid="table2-0272989X13480130">Table 2</xref>).</p>
<table-wrap id="table2-0272989X13480130" position="float">
<label>Table 2</label>
<caption>
<p>Model Diagnostics</p>
</caption>
<graphic alternate-form-of="table2-0272989X13480130" xlink:href="10.1177_0272989X13480130-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Model 1</th>
<th align="center">Model 2: Full Data Set</th>
<th align="center">Model 2: Excluding Item 13</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data points</td>
<td>2</td>
<td>24</td>
<td>23</td>
</tr>
<tr>
<td>pD (the effective number of parameters)</td>
<td>1.90</td>
<td>19.4</td>
<td>18.6</td>
</tr>
<tr>
<td>Deviance information criteria</td>
<td>13.12</td>
<td>169.7</td>
<td>155.6</td>
</tr>
<tr>
<td>Posterior mean deviance (the sum of the deviance contribution of each data point)</td>
<td>1.946</td>
<td>31.0</td>
<td>23.8</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Model 2 has random effects for the diagnostic thresholds and the accuracy parameters for the test, and noninformative gamma (0.001, 0.001) priors for the between-study precision parameters. Several alternative parameterizations were considered. A model with “independent” study effects assumed that the difference in DOR between the 2 tests was independent for each study. This model did not converge because it does not use the data from the other studies to inform the ROC curves for the RCT, and there are insufficient data in the RCT alone to estimate the sensitivity and specificity of the tests.</p>
<p>A “common treatment effect” model assumed that the difference in DOR between the 2 tests was the same in all 3 studies. Assuming a common treatment effect gave higher DIC and deviances than the base case model, indicating that this parameterization was insufficiently flexible. Using uniform priors for the between study standard deviations did not greatly affect the model estimates.</p>
</sec>
<sec id="section19-0272989X13480130">
<title>Sensitivity Analysis</title>
<p>A sensitivity analysis was conducted estimating what the impact on adverse events and costs would have been if compliance had been the same in both groups and if the test strategies only differed in sensitivity and specificity. The difference in the rate of adverse events reduced to 0.0009 per patient-day (95% CI 0.0001–0.0019), and the difference in costs (blood test minus urine test) increased to €0.369 per patient per day (95% CI 0.100–0.571).</p>
<p>Other model structures were also considered, but results are not reported in this article. A simpler structure with no distinction between sick days and high glucose days was implemented but showed a poor fit with the data. A bivariate random effects model was also tried with an explicit correlation between <italic>mu.alpha</italic><sub>1</sub> and <italic>mu.alpha</italic><sub>2</sub> (representing the log-diagnostic odds ratios of the 2 tests) and a Wishart prior for the covariances. Initial results also showed a poor fit, and this model was not developed further.</p>
</sec>
</sec>
<sec id="section20-0272989X13480130" sec-type="discussion">
<title>Discussion</title>
<p>There is often a choice of structure and data for decision models. In this article we show that MPES allows these issues to be dealt with more fully. MPES integrates model specification, parameter estimation, prediction, and validation in a single package, allowing alternative model structures and data to be formally compared. MPES offers the flexibility of using data on functions of parameters, data that would be excluded in conventional decision modeling. We applied MPES to a decision problem where blood ketone testing is compared with urine ketone testing in young people with Type 1 diabetes.</p>
<p>Our simplest model (Model 1) had only 2 states (before and after the adverse event) and 2 parameters (the rate of adverse events with the urine ketone test and the relative effect of the blood ketone test). In general, adding additional states or outcomes (e.g., positive and negative test results) to a decision model might offer one or several improvements. A positive test result is an intermediate or surrogate outcome expected to be a strong predictor of adverse events; therefore, including the test result as an outcome might improve the accuracy and precision of predictions (internal validity). In this case, the structure (representing our theory or prior knowledge) acts to reduce “noise” (variability in the data that is unexplained by the model).<sup><xref ref-type="bibr" rid="bibr2-0272989X13480130">2</xref></sup> Including additional outcomes as states in the model can allow the analyst to bring in a greater quantity and diversity of data. Increasing the amount of data (relative to the number of parameters) may improve the reliability of parameter estimates and model predictions (although there is also a risk of inconsistency). Adding further outcomes as states might improve predictions of economic quantities. In our example, costs are influenced by treatment administered, which in turn depends on diagnostic test results. Model 2 can make predictions in populations that differ in certain ways from the population from which the RCT was sampled (external validity). In our example, we could make predictions for a population at higher baseline risk by changing the probability of a sick day <italic>(p.sick</italic> or <italic>p.gluc)</italic>, assuming other parameters remain at previous values.</p>
<p>Model 1 estimates or confirms that the intervention is more effective but does not explain how it works.<sup><xref ref-type="bibr" rid="bibr10-0272989X13480130">10</xref>,<xref ref-type="bibr" rid="bibr21-0272989X13480130">21</xref></sup> This might not matter if the goal is primarily to predict the difference in adverse events between the 2 strategies in a population similar to the clinical study. However, in a pragmatic design analyzed by intention-to-treat (ITT), where not all patients strictly follow the protocol, it might not be clear what the “ITT strategy” actually is or how it might be implemented in practice.<sup><xref ref-type="bibr" rid="bibr22-0272989X13480130">22</xref></sup> Decision makers might wish to know why a policy of offering blood ketone testing is more effective. Is it because the blood ketone test is more accurate, or more likely to be used by patients according to protocol, or a combination of reasons? The trial investigators raised these questions but did not fully answer them, because they could not link these factors to the trial outcomes.<sup><xref ref-type="bibr" rid="bibr14-0272989X13480130">14</xref></sup> A more complex model might be more able to quantify the independent effect of each mechanism. We illustrated how such a model (Model 2) could be implemented using MPES. It would not have been possible to use a conventional decision model (implemented in packages such as Excel or TreeAge) in this case because direct data were not available on the specificity and sensitivity of the tests. The MPES estimated that the blood ketone test is effective (as used in the RCT) with a sensitivity and specificity close to 1, whereas the urine ketone test had a sensitivity of 0.88 and a specificity of 0.96.</p>
<p>MPES offers a comprehensive framework for decision model implementation and validation. MPES has the flexibility to permit more complex model structures and the use of a more diverse data set. However, a more complex model and/or diverse data sources also risk overfitting, inconsistency, and bias, illustrating the importance of adequate validation.<sup><xref ref-type="bibr" rid="bibr1-0272989X13480130">1</xref>,<xref ref-type="bibr" rid="bibr3-0272989X13480130">3</xref></sup> An important advantage of MPES is that it allows assessment of goodness of fit and the identification of potential sources of bias or inconsistency. In the example implemented, MPES was used to check the consistency of data points from diverse sources. Excluding data item 13 seemed to improve the model fit as measured by the sum of deviances. If data are found to be inconsistent, there may be a case for excluding these studies, for example on the grounds that they are biased (not measuring the relevant population). However, it may be more difficult to justify excluding a single item from a study while including other items from the same study, without specific evidence of bias in the estimation of that individual data point (and not others). Methods are needed for assessing the consistency of evidence in MPES when several data items are from the same study.</p>
<p>MPES also allowed validation of different parameterizations of Model 2 using statistical measures of goodness of fit. However, subjective assessment of “face validity” or plausibility using subject knowledge is still crucial.<sup><xref ref-type="bibr" rid="bibr2-0272989X13480130">2</xref></sup> Model 2 incorporates several “structural” assumptions that were not testable, at least with the data available here. It is assumed (rather than demonstrated) that patients with a true-positive test result will take appropriate action and avoid an adverse event. Likewise, it is assumed that patients with a true-negative test result are not at risk of an adverse event. We assume that DKA can only occur after a false-negative result and hypoglycemia can only occur after a false-positive result. As with all model assumptions, if false model predictions may be biased. Although implementing a model using MPES can use data better and more fully, eliciting expert opinion may still be justified.<sup><xref ref-type="bibr" rid="bibr23-0272989X13480130">23</xref></sup></p>
</sec>
</body>
<back>
<app-group>
<app id="app1-0272989X13480130">
<title>Appendix</title>
<sec id="section21-0272989X13480130">
<title>Winbugs Code</title>
<p>model</p>
<p>[</p>
<p>for(num in 1:14)[ #Binomial likelihoods</p>
<p>   R[num]~dbin(P[num],N[num])</p>
<p>    ]</p>
<p>#Poisson likelihoods</p>
<p>R[15]~dpois(all.b)#rate of adverse events in blood test</p>
<p>R[16]~dpois(all.u)#rate of adverse events in urine test</p>
<p>#False positive rate and sensitivity</p>
<p>for(num in 17:nData.1)[</p>
<p>    R[num]~dbin(P[num],N[num])</p>
<p>    ]</p>
<p>#study 1 Bektas</p>
<p>P[17]&lt;-fpr[1,1]#blood test FPR</p>
<p>P[18]&lt;-fpr[1,2]#urine test FPR</p>
<p>P[19]&lt;-sens[1,1]#blood test TPR</p>
<p>P[20]&lt;-sens[1,2]#urine test TPR</p>
<p>#study 2 Guerci</p>
<p>P[21]&lt;-fpr[2,1]#blood test FPR</p>
<p>P[22]&lt;-fpr[2,2]#urine test FPR</p>
<p>P[23]&lt;-sens[2,1]#blood test TPR</p>
<p>P[24]&lt;-sens[2,2]#urine test TPR</p>
<p>for (i in 1:3)[ #ROC curves in study 1, 2 and 3</p>
<p>alpha[i,1]~dnorm(mu.alpha[1],prec[1])#accuracy of blood test in study i</p>
<p>alpha[i,2]~dnorm(mu.alpha[2],prec[1])#accuracy of urine test in study i,</p>
<p>logitFPR[i,1]&lt;-theta[i]-0.5 * (alpha[i,1]) #logitFPR in blood test</p>
<p>logitTPR[i,1]&lt;-theta[i]+0.5 * (alpha[i,1]) #logitTPR in blood test</p>
<p>logitFPR[i,2]&lt;-theta[i]-0.5 * alpha[i,2] #logitFPR in urine test</p>
<p>logitTPR[i,2]&lt;-theta[i]+0.5 * alpha[i,2] #logitTPR in urine test</p>
<p>logit(fpr[i,1])&lt;-logitFPR[i,1]</p>
<p>logit(sens[i,1])&lt;-logitTPR[i,1]</p>
<p>logit(fpr[i,2])&lt;-logitFPR[i,2]</p>
<p>logit(sens[i,2])&lt;-logitTPR[i,2]</p>
<p>theta[i]~dnorm(mu.theta,prec[2])#diagnostic threshold for study i</p>
<p>]</p>
<p>for(test in 1:2)[#</p>
<p>mu.alpha[test]~dnorm(0,0.0001)</p>
<p>sens.m[test]&lt;-sens[3,test]</p>
<p>spec.m[test]&lt;-1-fpr[3,test]</p>
<p>]</p>
<p>mu.theta~dnorm(0,0.0001)</p>
<p>for (param in 1:2)[#priors for between-study variability</p>
<p>prec[param]~dgamma(0.001,0.001)</p>
<p>sd[param]&lt;-pow(prec[param],-0.5)</p>
<p>]</p>
<p>a~dbeta(1,1) #sick day</p>
<p>z~dbeta(1,1) #constraint 1-a-b&gt;0 or 1-a&gt;b</p>
<p>b&lt;-z * (1-a) #high glucose day</p>
<p>c~dbeta(1,1) #take test on sick day in blood group</p>
<p>d~dbeta(1,1) #take test on high glucose day</p>
<p>e~dbeta(1,1) #take test on other day</p>
<p>f~dbeta(1,1) #Prevalence (high ketone level on sick day )</p>
<p>g~dbeta(1,1) #Prevalence (high ketone level on glucose day )</p>
<p>h~dbeta(1,1) #prevalence (high ketone on other day)</p>
<p>#vector P holds the expected probabilities</p>
<p>P[1]&lt;-a#sick day in both groups</p>
<p>P[2]&lt;-b#high glucose day in both groups</p>
<p>P[3]&lt;-c#take test on sick day in blood group</p>
<p>P[4]&lt;-d#take test on high glucose day</p>
<p>P[5]&lt;-e#take test on other day in blood group</p>
<p>P[6]&lt;-f * sens.m[1] + (1-f) * (1-spec.m[1]) #test positive on sick day</p>
<p>P[7]&lt;-g * sens.m[1] + (1-g) * (1-spec.m[1]) #test positive on high glucose day</p>
<p>P[8]&lt;-h * sens.m[1]+ (1-h) * (1-spec.m[1]) #test positive on other day</p>
<p>FN[1]&lt;-a * c * f * (1-sens.m[1]) + a * (1-c) * f + b * d * g * (1-sens.m[1]) + b * (1-d) * g+(1-a-b) * e * h * (1-sens.m[1]) + (1-a-b) * (1-e) * h#false negative (blood group)</p>
<p>FP[1]&lt;-a * c * (1-f) * (1-spec.m[1])+b * d * (1-g) * (1-spec.m[1]) + (1-a-b) * e * (1-h) * (1-spec.m[1]) # false positive (blood group)</p>
<p>#parameters in urine group</p>
<p>k~dbeta(1,1) #take test on sick day</p>
<p>l~dbeta(1,1) #take test on high glucose day</p>
<p>m~dbeta(1,1) #take test on other day</p>
<p>P[9]&lt;-k#take test on sick day</p>
<p>P[10]&lt;-l#take test on high glucose day in urine group</p>
<p>P[11]&lt;-m#take test on other day in urine group</p>
<p>P[12]&lt;-f * sens.m[2] + (1-f) * (1-spec.m[2]) #test positive on sick day in urine group</p>
<p>P[13]&lt;-g * sens.m[2] + (1-g) * (1-spec.m[2]) #test positive on high glucose day in urine group</p>
<p>P[14]&lt;-h * sens.m[2]+ (1-h) * (1-spec.m[2]) #test positive when not sick or high glucose</p>
<p>FN[2]&lt;-a * k * f * (1-sens.m[2]) + a * (1-k) * f + b * l * g * (1-sens.m[2]) + b * (1-l) * g +(1-a-b) * m * h * (1-sens.m[2])+(1-a-b) * (1-m) * h#probability of false negative, urine group</p>
<p>FP[2]&lt;-a * k * (1-f) * (1-spec.m[2])+b * l * (1-g) * (1-spec.m[2]) + (1-a-b) * m * (1-h) * (1-spec.m[2]) #false positive, urine group</p>
<p>p.keta~dbeta(1,1) #ketacidosis given false negative</p>
<p>p.hypo~dbeta(1,1) #hypo given false positive</p>
<p>#predicted probabilities of adverse event (ketacidosis and hypo) in blood group</p>
<p>all.b&lt;-all.b.day * N[15]</p>
<p>all.b.day&lt;–log(1-P[15]) #convert probability to 1-day rate</p>
<p>#predicted probabilities of adverse event (ketacidosis and hypo) in blood group</p>
<p>P[15]&lt;-FN[1] * p.keta+FP[1] * p.hypo</p>
<p>all.u&lt;-all.u.day * N[16] #rate of adverse events in urine test</p>
<p>all.u.day&lt;–log(1-P[16])</p>
<p>P[16]&lt;-FN[2] * p.keta+FP[2] * p.hypo</p>
<p>diff[1]&lt;-(1-P[15])-(1-P[16])#difference in effectiveness (prob of event free survival)</p>
<p>diff[2]&lt;-(all.b.day/all.u.day)#alternative measure of effectiveness (ratio rates)</p>
<p>for (i in 1:(nData.1))[ #Diagnostics</p>
<p>rhat[i]&lt;-P[i] * N[i]</p>
<p>dev[i]&lt;-2 * (R[i] * (log(R[i])-log(rhat[i]))+(N[i]-R[i]) * (log(N[i]-R[i])-log(N[i]-rhat[i])))</p>
<p>]</p>
<p>sumdev&lt;-sum(dev[])#sum of deviance contributions</p>
<p>#Prediction of mean ROC</p>
<p>alpha.new[1]&lt;-mu.alpha[1]</p>
<p>alpha.new[2]&lt;-mu.alpha[2]</p>
<p>for (xx in 1:10)[</p>
<p>logit(fpr.c[xx,1])&lt;-th[xx]-0.5 * alpha.new[1] #logitFPR in blood test</p>
<p>logit(tpr.c[xx,1])&lt;-th[xx]+0.5 * alpha.new[1] #logitTPR in blood test</p>
<p>logit(fpr.c[xx,2])&lt;-th[xx]-0.5 * alpha.new[2] #logitFPR in urine test</p>
<p>logit(tpr.c[xx,2])&lt;-th[xx]+0.5 * alpha.new[2] #logitTPR in urine test</p>
<p>]</p>
<p>]#end model</p>
<p>list(#initial values</p>
<p>theta=c(0,0,0), mu.alpha=c(6,6),</p>
<p>alpha=structure(.Data=c(10,10,10,10,10,10),.Dim=c(3,2)),</p>
<p>prec=c(1,1), mu.theta=0,</p>
<p>a=0.1,z=0.1,c=0.1,d=0.1,e=0.1,f=0.1,</p>
<p>g=0.1,h=0.001,k=0.1,l=0.1, m=0.1,</p>
<p>p.hypo=0.1, p.keta=0.1</p>
<p>)</p>
<p>list(#data</p>
<p>th=c(-4,-3,-2,-1,0,1,2,3,4,5),</p>
<p>nData.1=24,#number of binomial data points other than lab studies</p>
<p>R=c(578,3327,#number of sick and high glucose days (both groups)</p>
<p>276,705,885,20,23,0,#days test is taken and positive tests in blood group</p>
<p>168,432,1198,26,18,58,#days test is taken and positive tests in urine group</p>
<p>11,22,#adverse events in blood and urine groups</p>
<p>16,20,#Bektas, false positives: blood, urine</p>
<p>35,32,#Bektas, true positives: blood, urine</p>
<p>0,0,#Guerci, false positives: blood, urine</p>
<p>13,10)#Guerci, true positives: blood, urine</p>
<p>,N=c(12934,12934,</p>
<p>304,2089,4383,276,705,885,</p>
<p>274,1238,4646,168,432,1198,</p>
<p>10910,10638,</p>
<p>91,91,48,48,</p>
<p>2,2,16,16)</p>
<p>)</p>
</sec>
</app>
</app-group>
<ack>
<p>We thank Dr. Gonzalo Piédrola Maroto of Hospital San Cecilio, University of Granada, Spain, for expert clinical opinion, and the 3 anonymous referees. An early draft of this article was presented at a seminar at the Centre for Health Economics, University of York. We are grateful to all of these for insightful and constructive comments.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="bibr1-0272989X13480130">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Caro</surname><given-names>J</given-names></name>
<name><surname>Briggs</surname><given-names>A</given-names></name>
<name><surname>Siebert</surname><given-names>U</given-names></name>
<name><surname>Kuntz</surname><given-names>K</given-names></name>
</person-group>. <article-title>Modeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force 1</article-title>. <source>Med Decis Making</source>. <year>2012</year>;<volume>32</volume>:<fpage>667</fpage>–<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr2-0272989X13480130">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Briggs</surname><given-names>AH</given-names></name>
<name><surname>Weinstein</surname><given-names>MC</given-names></name>
<name><surname>Fenwick</surname><given-names>EA</given-names></name>
<etal/>
</person-group>. <article-title>Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6</article-title>. <source>Med Decis Making</source>. <year>2012</year>;<volume>32</volume>(<issue>5</issue>):<fpage>722</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr3-0272989X13480130">
<label>3.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Steyerberg</surname><given-names>E</given-names></name>
</person-group>. <source>Clinical Prediction Models. A Practical Approach to Development, Validation, and Updating</source>. <publisher-name>New York: Springer</publisher-name>; <year>2009</year>.</citation>
</ref>
<ref id="bibr4-0272989X13480130">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Turner</surname><given-names>R</given-names></name>
<name><surname>Spiegelhalter</surname><given-names>D</given-names></name>
<name><surname>Smith</surname><given-names>G</given-names></name>
<name><surname>Thompson</surname><given-names>S</given-names></name>
</person-group>. <article-title>Bias modeling in evidence synthesis</article-title>. <source>J R Stat Soc Ser A Stat Soc</source>. <year>2009</year>;<volume>172</volume>(<issue>1</issue>):<fpage>21</fpage>–<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr5-0272989X13480130">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ades</surname><given-names>A</given-names></name>
<name><surname>Cliffe</surname><given-names>S</given-names></name>
</person-group>. <article-title>Markov chain Monte Carlo estimation of a multiparameter decision model: consistency of evidence and the accurate assessment of uncertainty</article-title>. <source>Med Decis Making</source>. <year>2002</year>;<volume>22</volume>(<issue>4</issue>):<fpage>359</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr6-0272989X13480130">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sutton</surname><given-names>AJ</given-names></name>
<name><surname>Cooper</surname><given-names>NJ</given-names></name>
<name><surname>Goodacre</surname><given-names>S</given-names></name>
<name><surname>Stevenson</surname><given-names>M</given-names></name>
</person-group>. <article-title>Integration of meta-analysis and economic decision modeling for evaluating diagnostic tests</article-title>. <source>Med Decis Making</source>. <year>2008</year>;<volume>28</volume>(<issue>5</issue>):<fpage>650</fpage>–<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr7-0272989X13480130">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Riley</surname><given-names>RD</given-names></name>
<name><surname>Abrams</surname><given-names>KR</given-names></name>
<name><surname>Lambert</surname><given-names>PC</given-names></name>
<name><surname>Sutton</surname><given-names>AJ</given-names></name>
<name><surname>Thompson</surname><given-names>JR</given-names></name>
</person-group>. <article-title>An evaluation of bivariate random-effects meta-analysis for the joint synthesis of two correlated outcomes</article-title>. <source>Stat Med</source>. <year>2007</year>;<volume>26</volume>(<issue>1</issue>):<fpage>78</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr8-0272989X13480130">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Riley</surname><given-names>RD</given-names></name>
<name><surname>Sutton</surname><given-names>AJ</given-names></name>
<name><surname>Abrams</surname><given-names>KR</given-names></name>
<name><surname>Lambert</surname><given-names>PC</given-names></name>
</person-group>. <article-title>Sensitivity analyses allowed more appropriate and reliable meta-analysis conclusions for multiple outcomes when missing data was present</article-title>. <source>J Clin Epidemiol</source>. <year>2004</year>;<volume>57</volume>(<issue>9</issue>):<fpage>911</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr9-0272989X13480130">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Higgins</surname><given-names>J</given-names></name>
<name><surname>Thompson</surname><given-names>S</given-names></name>
<name><surname>Spiegelhalter</surname><given-names>D</given-names></name>
</person-group>. <article-title>A re-evaluation of random-effects meta-analysis</article-title>. <source>J R Stat Soc Ser A Stat Soc</source>. <year>2009</year>;<volume>172</volume>(<issue>1</issue>):<fpage>137</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr10-0272989X13480130">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aalen</surname><given-names>O</given-names></name>
<name><surname>Roysland</surname><given-names>K</given-names></name>
<name><surname>Gran</surname><given-names>J</given-names></name>
</person-group>. <article-title>Causality, mediation and time: a dynamic viewpoint</article-title>. <source>J R Stat Soc Ser A Stat Soc</source>. <year>2012</year>;<volume>175</volume>(<issue>4</issue>):<fpage>831</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr11-0272989X13480130">
<label>11.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Spiegelhalter</surname><given-names>D</given-names></name>
<name><surname>Thomas</surname><given-names>A</given-names></name>
<name><surname>Best</surname><given-names>N</given-names></name>
<name><surname>Lunn</surname><given-names>D</given-names></name>
</person-group>. <source>WinBUGS User Manual: Version 1.4</source>. <publisher-loc>Cambridge, UK</publisher-loc>: <publisher-name>MRC Biostatistics Unit</publisher-name>.</citation>
</ref>
<ref id="bibr12-0272989X13480130">
<label>12.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Espin</surname><given-names>J</given-names></name>
<name><surname>Garcia Mochon</surname><given-names>L</given-names></name>
<name><surname>Epstein</surname><given-names>D</given-names></name>
</person-group>. <article-title>Economic Evaluation of Monitoring Systems for Blood Ketone for the Diagnosis and Prevention of Ketoacidosis [in Spanish]</article-title>. <publisher-loc>Seville, Spain</publisher-loc>: <publisher-name>Agencia de Evaluación de Tecnologías Sanitarias de Andalucía (AETSA)</publisher-name>; <year>2007</year>.</citation>
</ref>
<ref id="bibr13-0272989X13480130">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laffel</surname><given-names>LM</given-names></name>
</person-group>. <article-title>Challenges and opportunities in diabetes care: improving outcomes with education, disease management, and new technologies</article-title>. <source>Manag Care</source>. <year>2004</year>;<volume>13</volume>(<issue>4 Suppl</issue>):<fpage>15</fpage>–<lpage>8</lpage>; discussion 9–21.</citation>
</ref>
<ref id="bibr14-0272989X13480130">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laffel</surname><given-names>LM</given-names></name>
<name><surname>Wentzell</surname><given-names>K</given-names></name>
<name><surname>Loughlin</surname><given-names>C</given-names></name>
<name><surname>Tovar</surname><given-names>A</given-names></name>
<name><surname>Moltz</surname><given-names>K</given-names></name>
<name><surname>Brink</surname><given-names>S</given-names></name>
</person-group>. <article-title>Sick day management using blood 3-hydroxybutyrate (3-OHB) compared with urine ketone monitoring reduces hospital visits in young people with T1DM: a randomized clinical trial</article-title>. <source>Diabet Med</source>. <year>2006</year>;<volume>23</volume>(<issue>3</issue>):<fpage>278</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr15-0272989X13480130">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bahíllo</surname><given-names>MP</given-names></name>
<name><surname>Hermoso</surname><given-names>F</given-names></name>
<name><surname>Ochoa</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Incidence and prevalence of type 1 diabetes in children aged &lt;15 yr in Castilla-Leon (Spain)</article-title>. <source>Pediatr Diabetes</source>. <year>2007</year>;<volume>8</volume>(<issue>6</issue>):<fpage>369</fpage>–<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr16-0272989X13480130">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guerci</surname><given-names>B</given-names></name>
<name><surname>Benichou</surname><given-names>M</given-names></name>
<name><surname>Floriot</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Accuracy of an electrochemical sensor for measuring capillary blood ketones by fingerstick samples during metabolic deterioration after continuous subcutaneous insulin infusion interruption in type 1 diabetic patients</article-title>. <source>Diabetes Care</source>. <year>2003</year>;<volume>26</volume>(<issue>4</issue>):<fpage>1137</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr17-0272989X13480130">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bektas</surname><given-names>F</given-names></name>
<name><surname>Eray</surname><given-names>O</given-names></name>
<name><surname>Sari</surname><given-names>R</given-names></name>
<name><surname>Akbas</surname><given-names>H</given-names></name>
</person-group>. <article-title>Point of care blood ketone testing of diabetic patients in the emergency department</article-title>. <source>Endocr Res</source>. <year>2004</year>;<volume>30</volume>(<issue>3</issue>):<fpage>395</fpage>–<lpage>402</lpage>.</citation>
</ref>
<ref id="bibr18-0272989X13480130">
<label>18.</label>
<citation citation-type="web">
<collab>General Council of Official Colleges of Pharmacists of Spain</collab>. <article-title>BOT PLUS WEB database</article-title>. Available from: URL: <ext-link ext-link-type="uri" xlink:href="https://botplusweb.portalfarma.com/">https://botplusweb.portalfarma.com/</ext-link> <access-date>Accessed November 2008</access-date>.</citation>
</ref>
<ref id="bibr19-0272989X13480130">
<label>19.</label>
<citation citation-type="book">
<article-title>Andalusian Autonomous Government: Official Bulletin number 210</article-title>. Order of the 14th October 2005. Published <month>October</month> <day>27</day>, <year>2005</year>, <publisher-loc>Seville, Spain</publisher-loc>.</citation>
</ref>
<ref id="bibr20-0272989X13480130">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spiegelhalter</surname><given-names>D</given-names></name>
<name><surname>Best</surname><given-names>N</given-names></name>
<name><surname>Carlin</surname><given-names>B</given-names></name>
<name><surname>van der Linde</surname><given-names>A</given-names></name>
</person-group>. <article-title>Bayesian measures of model complexity and fit</article-title>. <source>J R Stat Soc Ser B Stat Methodol</source>. <year>2002</year>;<volume>64</volume>(<issue>4</issue>):<fpage>583</fpage>.</citation>
</ref>
<ref id="bibr21-0272989X13480130">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Box</surname><given-names>G</given-names></name>
</person-group>. <article-title>Science and statistics</article-title>. <source>J Am Stat Assoc</source>. <year>1976</year>;<volume>71</volume>(<issue>356</issue>):<fpage>791</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr22-0272989X13480130">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morden</surname><given-names>JP</given-names></name>
<name><surname>Lambert</surname><given-names>PC</given-names></name>
<name><surname>Latimer</surname><given-names>N</given-names></name>
<name><surname>Abrams</surname><given-names>KR</given-names></name>
<name><surname>Wailoo</surname><given-names>AJ</given-names></name>
</person-group>. <article-title>Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study</article-title>. <source>BMC Med Res Methodol</source>. <year>2011</year>;<volume>11</volume>:<fpage>4</fpage>.</citation>
</ref>
<ref id="bibr23-0272989X13480130">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soares</surname><given-names>MO</given-names></name>
<name><surname>Dumville</surname><given-names>JC</given-names></name>
<name><surname>Ashby</surname><given-names>RL</given-names></name>
<etal/>
</person-group>. <article-title>Methods to assess cost-effectiveness and value of further research when data are sparse: negative-pressure wound therapy for severe pressure ulcers</article-title>. <source>Med Decis Making</source>. <year>2013</year>;<volume>33</volume>(<issue>3</issue>):<fpage>416</fpage>–<lpage>437</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>